Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
In a poster presentation, the company will present final results from its Phase 2 POWER study of tildacerfont for the treatment of polycystic ovary syndrome (PCOS). In two other poster presentations, the company will highlight the comorbidities associated with congenital adrenal hyperplasia (CAH) and standard of care treatment, as well as the need to formalize transitionary care between pediatric and adult endocrinology practices to improve biochemical outcomes that reduce the risk of morbidity and mortality in adults with CAH.
ENDO 2024 Poster Presentation Details
Title: A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects with Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens
Session Title: P058 – Reproductive Endocrinology: Polycystic Ovary Syndrome
Session Date & Time: 12:00 –
Presenter:
Authors:
Title: Impact of Geography and Insurance on Healthcare Utilization Preferences of Individuals with Congenital Adrenal Hyperplasia
Session Title: P023 – Adrenal (Excluding Mineralocorticoids): Health Disparities in Adrenal
Session Date & Time: 12:15 –
Presenter:
Authors:
Title: The Treatment May Be Worse Than the Disease: The Real-World Clinical Burden of Disease and Treatment in Congenital Adrenal Hyperplasia
Session Title: P023 – Adrenal (Excluding Mineralocorticoids): Health Disparities in Adrenal
Session Date & Time: 12:15 –
Presenter:
Authors:
The poster presentations will be available on the company’s website at the time of their respective poster sessions. Access more information about ENDO 2024 here.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20240522604348/en/
Media
Inizio Evoke Comms
(937) 232-4889
Katherine.Beach@inizioevoke.com
media@sprucebio.com
Investors
President and CFO
investors@sprucebio.com
Source: